Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Avalo Therapeutics, Inc. has received a consensus recommendation of "Moderate Buy" from ten research firms, with an average target price of $31.67 per share.
• The company's stock is trading at $13.95, down 6.8%, and has a fifty-two week range between $3.39 and $16.00.
• Avalo's recent quarterly earnings showed a loss of ($1.92) per share, missing the consensus estimate by ($0.49).

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the ten research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $31.6667.

AVTX has been the subject of several analyst reports. BTIG Research reissued a "buy" rating and set a $40.00 price target on shares of Avalo Therapeutics in a report on Monday, September 29th. HC Wainwright increased their price target on shares of Avalo Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a report on Wednesday, September 17th. TD Cowen began coverage on shares of Avalo Therapeutics in a report on Friday, September 5th. They issued a "buy" rating for the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Avalo Therapeutics in a report on Saturday, September 27th. Finally, Cantor Fitzgerald began coverage on shares of Avalo Therapeutics in a report on Friday, August 15th. They issued an "overweight" rating for the company.

Avalo Therapeutics Trading Down 6.8%

Shares of AVTX opened at $13.95 on Friday. Avalo Therapeutics has a fifty-two week low of $3.39 and a fifty-two week high of $16.00. The firm has a 50-day simple moving average of $10.71 and a 200-day simple moving average of $7.04.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.49). Equities research analysts predict that Avalo Therapeutics will post -19.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Allostery Investments LP increased its holdings in Avalo Therapeutics by 46.1% in the first quarter. Allostery Investments LP now owns 107,141 shares of the company's stock valued at $858,000 after buying an additional 33,827 shares in the last quarter. Affinity Asset Advisors LLC grew its position in shares of Avalo Therapeutics by 19.3% in the first quarter. Affinity Asset Advisors LLC now owns 657,154 shares of the company's stock valued at $5,264,000 after purchasing an additional 106,389 shares during the last quarter. Nantahala Capital Management LLC acquired a new stake in shares of Avalo Therapeutics in the first quarter valued at approximately $7,209,000. RWA Wealth Partners LLC acquired a new stake in shares of Avalo Therapeutics in the first quarter valued at approximately $2,505,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Avalo Therapeutics in the first quarter valued at approximately $80,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.